GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership with CureVac N.V. (Nasdaq: CVAC), a German mRNA specialist. The revised agreement will grant GSK full global rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19, encompassing related combination regimens.
As per the deal terms, GSK will pay an upfront fee of EUR 400 million (USD 431 million) and is committed to potential additional payments of up to EUR 1.05 billion (USD 1.1 billion) tied to development and sales milestones, plus tiered royalties on future sales.
The collaboration between GSK and CureVac on mRNA vaccine development for infectious diseases began in 2020. That deal involved GSK taking a EUR 150 million equity stake in CureVac and an upfront payment of EUR 120 million. This week’s financial terms supersede the previous arrangements. CureVac will receive exclusive rights to unspecified preclinically validated infectious disease targets from the 2020 collaboration, with the liberty to independently develop and partner mRNA vaccines for other infectious diseases or indications beyond influenza and COVID-19.- Flcube.com
